WASHINGTON — The pharmaceutical industry’s Washington lobbying group is fighting full force to scuttle a Trump administration policy proposal that would tie the price of drugs in the U.S. to their costs abroad — and making a handful of specious arguments along the way, health policy experts told STAT.

PhRMA has launched a multipronged attack against the proposal, arguing that it would, in effect, make health care in America more closely resemble systems in Europe. Patients wouldn’t be able to get as many new drugs and might suffer as a result, they say.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • The above critiques are straw man arguments, but it would be great to further report on legitimate critiques.

    Specifically, the opinion piece, written on this website a week or so ago, titled “Drug Pricing Conversations Must Include the Cost of Innovation”, is a very clear description of the trade-offs at hand. STATNews can be a place for informative conversations around these real trade-offs, not just in opinion pieces, but pressing those who try to ignore those trade-offs (politicians, policy makers, advocates) for on-the-record acknowledgement of these facts.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy